RUTH ROMAN-LLADO

Dr. RUTH ROMAN-LLADO

Laboratory of Oncology, Pangaea Oncology, Dexeus University Hospital, Barcelona, Catalonia, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
CECristina Esteban
Cristina Esteban
Ana Giménez-CapitánAna Giménez-Capitán
Ana Giménez-Capitán
RRRUTH ROMAN-LLADO
RUTH ROMAN-LLADO
SRSonia Rodríguez
Sonia Rodríguez
NJNúria Jordana-Ariza
Núria Jordana-Ariza
Miguel Ángel Molina-VilaMiguel Ángel Molina-Vila
Miguel Ángel Molina-Vila
The detection of ALK receptor tyrosine kinase (ALK), ROS proto-oncogen1, receptor tyrosine kinase (ROS1), ret proto-oncogen (RET), and MET proto-oncogen exon 14 skipping (METΔex14) allows for the selection of specific kinase inhibitor treatment in patients with non-small cell lung cancer (NSCLC). Multiplex technologies are recommended in this setting. We used nCounter, a multiplexed technology based on RNA hybridization, to detect ALK, ROS1, RET, and METΔex14 in RNA purified from cytological specimens (n = 16) and biopsies (n = 132). Twelve of the 16 cytological samples (75.0%) were evaluable by nCounter compared to 120 out of 132 (90.9%) biopsies. The geometrical mean (geomean) of the housekeeping genes of the nCounter panel, but not the total amount of RNA purified, was significantly higher in biopsies vs. cytological samples. Among cytological samples, we detected ALK (n = 3), METΔex14 (n = 1) and very high MET expression (n = 1) positive cases. The patient with METΔex14 had a partial response to tepotinib, one of the patients with ALK fusions was treated with crizotinib with a complete response. Cell blocks and cytological extensions can be successfully used for the detection of fusions and splicing variants using RNA-based methods such as nCounter.

Verified
Journal Article
Open access
PDF file
MVMarta Vives-Usano
Marta Vives-Usano
BPBeatriz García Pelaez
Beatriz García Pelaez
RRRUTH ROMAN-LLADO
RUTH ROMAN-LLADO
MIMónica Garzón Ibañez
Mónica Garzón Ibañez
EAErika Aldeguer
Erika Aldeguer
CMClara Mayo
Clara Mayo
Somatic copy number variations (CNV; i.e., amplifications and deletions) have been implicated in the origin and development of multiple cancers and some of these aberrations are designated targets for therapies. Although FISH is still considered the gold standard for CNV detection, the increasing number of potentially druggable amplifications to be assessed makes a gene-by-gene approach time- and tissue-consuming. Here we investigated the potential of next generation sequencing (NGS) custom panels to simultaneously determine CNVs across FFPE solid tumor samples. DNA was purified from cell lines and FFPE samples and analyzed by NGS sequencing using a 20-gene custom panel in the GeneReader Platform®. CNVs were identified using an in-house algorithm based on the UMI read coverage. Retrospective validation of in-house algorithm to identify CNVs showed 97.1% concordance rate with the NGS custom panel. The prospective analysis was performed in a cohort of 243 FFPE samples from patients arriving at our hospital, which included 74 NSCLC tumors, 148 CRC tumors, and 21 other tumors. Of them, 33% presented CNVs by NGS and in 14 cases (5.9%) the CNV was the only alteration detected. We have identified CNV alterations in about one-third of our cohort, including FGFR1, CDK6, CDK4, EGFR, MET, ERBB2, BRAF, or KRAS. Our work highlights the need to include CNV testing as a part of routine NGS analysis in order to uncover clinically relevant gene amplifications that can guide the selection of therapies.

Verified
Journal Article
Open access
PDF file
RRRUTH ROMAN-LLADO
RUTH ROMAN-LLADO
CECristina Esteban
Cristina Esteban
NJNúria Jordana-Ariza
Núria Jordana-Ariza
JRJaume Roca-Arias
Jaume Roca-Arias
SRSonia Rodríguez
Sonia Rodríguez
Miguel Ángel Molina-VilaMiguel Ángel Molina-Vila
Miguel Ángel Molina-Vila
Genetic and drug sensitivity assays on primary cultures are not only of basic but also of translational interest and could eventually aid oncologists in the selection of treatments. However, cancer cells need to be identified and differentiated from the non-tumor cells always present in primary cultures. Also, successive passages can change the proportions of these two subpopulations. In this study, we propose fluorescence in situ hybridization (FISH) analysis on cell smears to determine the presence of tumor cells in primary cultures obtained from patients carrying translocations or copy number gains. FISH proved to be an easy, fast, economic, and reliable method of characterizing cell populations, which could be used repeatedly at different passages to monitor variations and to confirm the maintenance of translocations and copy number gains throughout the culture process.